Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1981 1
1989 1
1990 1
1991 2
1992 4
1993 6
1994 3
1995 19
1996 24
1997 27
1998 26
1999 23
2000 16
2001 15
2002 13
2003 43
2004 26
2005 33
2006 57
2007 50
2008 46
2009 33
2010 34
2011 49
2012 48
2013 55
2014 47
2015 59
2016 56
2017 57
2018 49
2019 54
2020 73
2021 69
2022 50
2023 37

Text availability

Article attribute

Article type

Publication date

Search Results

1,078 results

Results by year

Filters applied: . Clear all
Page 1
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. Page MJ, et al. Among authors: bossuyt pm. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71. BMJ. 2021. PMID: 33782057 Free PMC article.
PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE. Page MJ, et al. Among authors: bossuyt pm. BMJ. 2021 Mar 29;372:n160. doi: 10.1136/bmj.n160. BMJ. 2021. PMID: 33781993 Free PMC article.
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. Torres J, et al. Among authors: bossuyt p. J Crohns Colitis. 2020 Jan 1;14(1):4-22. doi: 10.1093/ecco-jcc/jjz180. J Crohns Colitis. 2020. PMID: 31711158 Free article. No abstract available.
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.
Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, Doherty G, El-Hussuna A, Ellul P, Fiorino G, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gisbert JP, Gomollon F, González Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Kucharzik T, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Stassen L, Torres J, Uzzan M, Vavricka S, Verstockt B, Zmora O. Adamina M, et al. Among authors: bossuyt p. J Crohns Colitis. 2020 Feb 10;14(2):155-168. doi: 10.1093/ecco-jcc/jjz187. J Crohns Colitis. 2020. PMID: 31742338 Free article.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Among authors: bossuyt p. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. Page MJ, et al. Among authors: bossuyt pm. Syst Rev. 2021 Mar 29;10(1):89. doi: 10.1186/s13643-021-01626-4. Syst Rev. 2021. PMID: 33781348 Free PMC article. No abstract available.
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. Page MJ, et al. Among authors: bossuyt pm. PLoS Med. 2021 Mar 29;18(3):e1003583. doi: 10.1371/journal.pmed.1003583. eCollection 2021 Mar. PLoS Med. 2021. PMID: 33780438 Free PMC article.
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. Page MJ, et al. Among authors: bossuyt pm. J Clin Epidemiol. 2021 Jun;134:178-189. doi: 10.1016/j.jclinepi.2021.03.001. Epub 2021 Mar 29. J Clin Epidemiol. 2021. PMID: 33789819 Free article.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Ferrante M, et al. Among authors: bossuyt p. Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4. Lancet. 2022. PMID: 35644155 Clinical Trial.
1,078 results